Maratha Vidya Prasarak Samaj's
Dr. Vasantrao Pawar Medical College, Hospital & Research Centre
Vasantdada nagar, Adgaon, Nashik, Maharashtra - 422 003

(Annexure 9)

Serious Adverse Event Reporting Format(Clinical trials)

EC Ref. No.*(for office use):*

Title of study: Principal Investigator (Name, Designation and Affiliation)

1. Participant details :

Initials and Case No./Subject ID	Age at the time of event:	Gender	Weight: (Kgs)
		Male ☐ Female ☐	Height: (cms)

2. Report type: Initial ☐ Follow-up ☐ Final ☐

If Follow-up report, state date of Initial report Click here to enter a date.

What was the assessment of relatedness to the trial in the initial report?

By PI- Related ☐	By sponsor - Related ☐	By EC - Related ☐
Unrelated ☐	Unrelated ☐	Unrelated ☐

3. Describe the event and specify suspected SAE diagnosis:

4. Date of onset of SAE: Date of reporting:

5. Onset lag time after administration of intervention: Location of SAE (Clinic/Ward/Home/Other)

6. Details of suspected study drug/device/investigational procedure causing SAE:

   I. Suspect study drug (include generic name) device/intervention:
   II. Indication(s) for which suspect study drug was prescribed or tested:
   III. Route(s) of administration, daily dose and regimen, dosage form and strength:
   IV. Therapy start date: Stop date:

7. Was study intervention discontinued due to event? Yes ☐ No ☐

8. Did the reaction decline after stopping or reducing the dosage of the study drug / procedure?
Yes ☐ No ☐

If yes, provide details about the reduced dose.

9. Did the reaction reappear after reintroducing the study drug / procedure? Yes ☐ No ☐ NA ☐

If yes, provide details about the dose.

10. Concomitant study drugs history and lab investigations:

I. Concomitant study drug (s) and date of administration:

II. Relevant test/laboratory data with dates:

III. Patient relevant history including pre-existing medical conditions (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/ renal dysfunction etc)

11. Have any similar SAE occurred previously in this study? If yes, please provide details. Yes ☐ No ☐

12. Seriousness of the SAE:

Death	☐	Congenital anomaly	☐
Life threatening	☐	Required intervention to prevent permanent impairment / damage	☐
Hospitalization-initial or prolonged	☐		
Disability		Others (specify)	☐

13. Describe the medical management provided for adverse reaction (if any) to the research participant. (Include information on who paid, how much was paid and to whom).

14. Outcome of SAE:

Fatal	☐	Recovered	☐
Continuing	☐	Unknown	☐
Recovering	☐	Other (specify)	☐

15. Was the research subject continued on the trial? Yes ☐ No ☐ NA ☐

16. Provide the details about PI final assessment of SAE relatedness to trial.

17. Has this information been communicated to sponsor/CRO/regulatory agencies? Yes ☐ No ☐

Provide details if communicated (including date)

18. Does this report require any alteration in trial protocol? Yes ☐ No ☐

19. Provide details of compensation provided/ to be provided the participants (include information on who pays, how much, and to whom):

Signature of PI:

Date: